Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 6/2013

01-12-2013 | Review

Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences

Authors: Eduardo López-Collazo, Carlos del Fresno

Published in: Critical Care | Issue 6/2013

Login to get access

Abstract

Endotoxin tolerance was first described in a study that exposed animals to a sublethal dose of bacterial endotoxin. The animals subsequently survived a lethal injection of endotoxin. This refractory state is associated with the innate immune system and, in particular, with monocytes and macrophages, which act as the main participants. Several mechanisms are involved in the control of endotoxin tolerance; however, a full understanding of this phenomenon remains elusive. A number of recent reports indicate that clinical examples of endotoxin tolerance include not only sepsis but also diseases such as cystic fibrosis and acute coronary syndrome. In these pathologies, the risk of new infections correlates with a refractory state. This review integrates the molecular basis and clinical implications of endotoxin tolerance in various pathologies.
Appendix
Available only for authorised users
Literature
1.
Goldszmid RS, Trinchieri G: The price of immunity. Nat Immunol 2012, 13: 932-938. 10.1038/ni.2422PubMed
2.
Kawai T, Akira S: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11: 373-384. 10.1038/ni.1863PubMed
3.
Kumar H, Kawai T, Akira S: Pathogen recognition by the innate immune system. Int Rev Immunol 2011, 30: 16-34. 10.3109/08830185.2010.529976PubMed
4.
Ramos HJ, Gale M Jr: RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol 2011, 1: 167-176. 10.1016/j.coviro.2011.04.004PubMedCentralPubMed
5.
Cavaillon JM, Adib-Conquy M: Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006, 10: 233. 10.1186/cc5055PubMedCentralPubMed
6.
Escoll P, del Fresno C, García L, Vallés G, Lendínez MJ, Arnalich F, López-Collazo E: Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 2003, 311: 465-472. 10.1016/j.bbrc.2003.10.019PubMed
7.
del Fresno C, Gómez-Piña V, Lores V, Soares-Schanoski A, Fernández-Ruiz I, Rojo B, Alvarez-Sala R, Caballero-Garrido E, García F, Veliz T, Arnalich F, Fuentes-Prior P, García-Río F, López-Collazo E: Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One 2008, 3: e2667. 10.1371/journal.pone.0002667PubMedCentralPubMed
8.
del Fresno C, Soler-Rangel L, Soares-Schanoski A, Gómez-Piña V, González-León MC, Gómez-García L, Mendoza-Barberá E, Rodríguez-Rojas A, García F, Fuentes-Prior P, Arnalich F, López-Collazo E: Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J Endotoxin Res 2007, 13: 39-52. 10.1177/0968051907078623PubMed
9.
Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, Tseng SC, Lin WP, Chen WT, Sheen IS: Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007, 46: 816-826. 10.1016/j.jhep.2006.12.018PubMed
10.
Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M: Reprogramming of circulatory cells in sepsis and SIRS. J Endotoxin Res 2005, 11: 311-320.PubMed
11.
Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, Hoedemaekers CW, Pickkers P: Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Crit Care Med 2011, 39: 1866-1870. 10.1097/CCM.0b013e3182190d5dPubMed
12.
Perry JA, Olver CS, Burnett RC, Avery AC: Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. J Immunol 2005, 174: 5921-5925.PubMed
13.
Greisman SE, Hornick RB, Wagner HN Jr, Woodward WE, Woodward TE: The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J Clin Invest 1969, 48: 613-629. 10.1172/JCI106020PubMedCentralPubMed
14.
Rubenstein M, Mulholland JH, Jeffery GM, Wolff SM: Malaria induced endotoxin tolerance. Proc Soc Exp Biol Med 1965, 118: 283-287. 10.3181/00379727-118-29820PubMed
15.
McCabe WR: Endotoxin tolerance. II. Its occurrence in patients with pyelonephritis. J Clin Invest 1963, 42: 618-625. 10.1172/JCI104752PubMedCentralPubMed
16.
Neva FA, Morgan HR: Tolerance to the action of endotoxins of enteric bacilli in patients convalescent from typhoid and paratyphoid fevers. J Lab Clin Med 1950, 35: 911-922.PubMed
17.
Fuentes-Prior P, Biswas SK, López-Collazo E, Prados C, Arnalich F, Gutierrez Del Arroyo A, García-Rio F, Gómez-Piña V, Soares-Schanoski A, Fernández-Ruíz I, Jurado T, Kajiji T, Shu C, Marín E, del Fresno C: Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J Immunol 2009, 182: 6494-6507. 10.4049/jimmunol.0803350PubMed
18.
Landoni VI, Chiarella P, Martire-Greco D, Schierloh P, Van-Rooijen N, Rearte B, Palermo MS, Isturiz MA, Fernandez GC: Tolerance to lipopolysaccharide promotes an enhanced neutrophil extracellular traps formation leading to a more efficient bacterial clearance in mice. Clin Exper Immunol 2012, 168: 153-163. 10.1111/j.1365-2249.2012.04560.x
19.
Mendes ME, Baggio-Zappia GL, Brunialti MK, Fernandes Mda L, Rapozo MM, Salomao R: Differential expression of toll-like receptor signaling cascades in LPS-tolerant human peripheral blood mononuclear cells. Immunobiology 2011, 216: 285-295. 10.1016/j.imbio.2010.07.008PubMed
20.
Chen X, El Gazzar M, Yoza BK, McCall CE: The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. J Biol Chem 2009, 284: 27857-27865. 10.1074/jbc.M109.000950PubMedCentralPubMed
21.
Freudenberg MA, Galanos C: Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun 1988, 56: 1352-1357.PubMedCentralPubMed
22.
Biswas SK, Lopez-Collazo E: Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009, 30: 475-487. 10.1016/j.it.2009.07.009PubMed
23.
Karp CL, Wysocka M, Ma X, Marovich M, Factor RE, Nutman T, Armant M, Wahl L, Cuomo P, Trinchieri G: Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. Eur J Immunol 1998, 28: 3128-3136. 10.1002/(SICI)1521-4141(199810)28:10<3128::AID-IMMU3128>3.0.CO;2-TPubMed
24.
Wolk K, Docke WD, von Baehr V, Volk HD, Sabat R: Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000, 96: 218-223.PubMed
25.
Lopez-Collazo E, Gomez-Pina V, Arnalich F: Understanding immune dysfunctions in sepsis patients. Crit Care 2010, 14: 435. 10.1186/cc9202PubMedCentralPubMed
26.
Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG: Inflammation and Host Response to Injury, Large Scale Collaborative Research Program: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110: 3507-3512. 10.1073/pnas.1222878110PubMedCentralPubMed
27.
de Souza N: Model organisms: mouse models challenged. Nat Methods 2013, 10: 288. 10.1038/nmeth.2429PubMed
28.
Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447: 972-978.PubMed
29.
Pena OM, Pistolic J, Raj D, Fjell CD, Hancock RE: Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J Immunol 2011, 186: 7243-7254. 10.4049/jimmunol.1001952PubMed
30.
Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110: 191-202. 10.1016/S0092-8674(02)00827-9PubMed
31.
Peng Q, O'Loughlin JL, Humphrey MB: DOK3 negatively regulates LPS responses and endotoxin tolerance. PLoS One 2012, 7: e39967. 10.1371/journal.pone.0039967PubMedCentralPubMed
32.
Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF: Inflammation and Host Response to Injury, Large Scale Collaborative Research Program: A network-based analysis of systemic inflammation in humans. Nature 2005, 437: 1032-1037. 10.1038/nature03985PubMed
33.
Dominguez-Soto A, Sierra-Filardi E, Puig-Kroger A, Perez-Maceda B, Gomez-Aguado F, Corcuera MT, Sanchez-Mateos P, Corbi AL: Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol 2011, 186: 2192-2200. 10.4049/jimmunol.1000475PubMed
34.
del Fresno C, Otero K, Gómez-García L, González-León MC, Soler-Ranger L, Fuentes-Prior P, Escoll P, Baos R, Caveda L, García F, Arnalich F, López-Collazo E: Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 2005, 174: 3032-3040.PubMed
35.
Medvedev AE, Kopydlowski KM, Vogel SN: Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol 2000, 164: 5564-5574.PubMed
36.
Sato S, Takeuchi O, Fujita T, Tomizawa H, Takeda K, Akira S: A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int Immunol 2002, 14: 783-791. 10.1093/intimm/dxf046PubMed
37.
Dobrovolskaia MA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, Cody MJ, Michalek SM, Rice NR, Vogel SN: Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR ‘homotolerance’ versus ‘heterotolerance’ on NF-kappa B signaling pathway components. J Immunol 2003, 170: 508-519.PubMed
38.
Biswas SK, Bist P, Dhillon MK, Kajiji T, Del Fresno C, Yamamoto M, Lopez-Collazo E, Akira S, Tergaonkar V: Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance. J Immunol 2007, 179: 4083-4092.PubMed
39.
Frellstedt L, McKenzie HC, Barrett JG, Furr MO: Induction and characterization of endotoxin tolerance in equine peripheral blood mononuclear cells in vitro . Vet Immunol Immunopathol 2012, 149: 97-102. 10.1016/j.vetimm.2012.05.012PubMed
40.
Xiong Y, Medvedev AE: Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20. J Leukoc Biol 2011, 90: 1141-1148. 10.1189/jlb.0611273PubMedCentralPubMed
41.
Petzl W, Gunther J, Pfister T, Sauter-Louis C, Goetze L, von Aulock S, Hafner-Marx A, Schuberth HJ, Seyfert HM, Zerbe H: Lipopolysaccharide pretreatment of the udder protects against experimental Escherichia coli mastitis. Innate Immun 2012, 18: 467-477. 10.1177/1753425911422407PubMed
42.
Draisma A, Pickkers P, Bouw MP, van der Hoeven JG: Development of endotoxin tolerance in humans in vivo. Crit Care Med 2009, 37: 1261-1267. 10.1097/CCM.0b013e31819c3c67PubMed
43.
Grutz G: New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005, 77: 3-15.PubMed
44.
Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk HD: Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995, 181: 1887-1892. 10.1084/jem.181.5.1887PubMed
45.
Berg DJ, Kuhn R, Rajewsky K, Muller W, Menon S, Davidson N, Grunig G, Rennick D: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995, 96: 2339-2347. 10.1172/JCI118290PubMedCentralPubMed
46.
Van der Poll T, de Vos AF, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES, Van't Veer C: Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007, 179: 7110-7120.PubMed
47.
Wiersinga WJ, van't Veer C, van den Pangaart PS, Dondorp AM, Day NP, Peacock SJ, van der Poll T: Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009, 37: 569-576. 10.1097/CCM.0b013e318194b1bfPubMed
48.
Stiehm M, Peters K, Wiesmuller KH, Bufe A, Peters M: A novel synthetic lipopeptide is allergy-protective by the induction of LPS-tolerance. Clin Exp Allergy 2013, 43: 785-797. 10.1111/cea.12116PubMed
49.
Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z: IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 1999, 274: 19403-19410. 10.1074/jbc.274.27.19403PubMed
50.
Janssens S, Beyaert R: Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003, 11: 293-302. 10.1016/S1097-2765(03)00053-4PubMed
51.
Mendoza-Barberá E, Corral-Rodríguez MA, Soares-Schanoski A, Velarde M, Macieira S, Messerschmidt A, López-Collazo E, Fuentes-Prior P: Contribution of globular death domains and unstructured linkers to MyD88.IRAK-4 heterodimer formation: an explanation for the antagonistic activity of MyD88s. Biochem Biophys Res Commun 2009, 380: 183-187. 10.1016/j.bbrc.2009.01.069PubMed
52.
López-Collazo E, Fuentes-Prior P, Arnalich F, del Fresno C: Pathophysiology of interleukin-1 receptor-associated kinase-M: implications in refractory state. Curr Opin Infect Dis 2006, 19: 237-244. 10.1097/01.qco.0000224817.35105.7dPubMed
53.
Domon H, Honda T, Oda T, Yoshie H, Yamazaki K: Early and preferential induction of IL-1 receptor-associated kinase-M in THP-1 cells by LPS derived from Porphyromonas gingivali s. J Leukoc Biol 2008, 83: 672-679.PubMed
54.
Liu ZJ, Yan LN, Li XH, Xu FL, Chen XF, You HB, Gong JP: Up-regulation of IRAK-M is essential for endotoxin tolerance induced by a low dose of lipopolysaccharide in Kupffer cells. J Surg Res 2008, 150: 34-39. 10.1016/j.jss.2007.12.759PubMed
55.
Gómez-Piña V, Martínez E, Fernández-Ruíz I, Del Fresno C, Soares-Schanoski A, Jurado T, Siliceo M, Toledano V, Fernández-Palomares R, García-Rio F, Arnalich F, Biswas SK, López-Collazo E: Role of MMPs in orchestrating inflammatory response in human monocytes via a TREM-1-PI3K-NF-kappaB pathway. J Leukoc Biol 2012, 91: 933-945. 10.1189/jlb.0711340PubMed
56.
Arts RJ, Joosten LA, van der Meer JW, Netea MG: TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors. J Leukoc Biol 2013, 93: 209-215. 10.1189/jlb.0312145PubMed
57.
Quinn EM, Wang J, Redmond HP: The emerging role of microRNA in regulation of endotoxin tolerance. J Leukoc Biol 2012, 91: 721-727. 10.1189/jlb.1111571PubMed
58.
Broad A, Jones DE, Kirby JA: Toll-like receptor (TLR) response tolerance: a key physiological ‘damage limitation’ effect and an important potential opportunity for therapy. Curr Med Chem 2006, 13: 2487-2502. 10.2174/092986706778201675PubMed
59.
Moller K: Of cells and men: ex vivo and in vivo tolerance to lipopolysaccharide. Crit Care Med 2011, 39: 1997-1998. 10.1097/CCM.0b013e3182249931PubMed
60.
Buras JA, Holzmann B, Sitkovsky M: Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005, 4: 854-865. 10.1038/nrd1854PubMed
61.
van der Poll T, Opal SM: Host-pathogen interactions in sepsis. Lancet 2008, 8: 32-43.PubMed
62.
Monneret G, Venet F, Pachot A, Lepape A: Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14: 64-78.PubMedCentralPubMed
63.
Munoz C, Carlet J, Fitting C, Misset B, Blériot JP, Cavaillon JM: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991, 88: 1747-1754. 10.1172/JCI115493PubMedCentralPubMed
64.
Munoz C, Misset B, Fitting C, Bleriot JP, Carlet J, Cavaillon JM: Dissociation between plasma and monocyte-associated cytokines during sepsis. European J Immunol 1991, 21: 2177-2184. 10.1002/eji.1830210928
65.
Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G: Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 2006, 106: 63-71. 10.1016/j.imlet.2006.04.010PubMed
66.
Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC: Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. J Lab Clin Med 2000, 135: 153-160. 10.1067/mlc.2000.104306PubMed
67.
Wysocka M, Robertson S, Riemann H, Caamano J, Hunter C, Mackiewicz A, Montaner LJ, Trinchieri G, Karp CL: IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J Immunol 2001, 166: 7504-7513.PubMed
68.
Murphey ED, Sherwood ER: Bacterial clearance and mortality are not improved by a combination of IL-10 neutralization and IFN-gamma administration in a murine model of post-CLP immunosuppression. Shock 2006, 26: 417-424. 10.1097/01.shk.0000226343.70904.4fPubMed
69.
Abe R, Hirasawa H, Oda S, Sadahiro T, Nakamura M, Watanabe E, Nakada TA, Hatano M, Tokuhisa T: Up-regulation of interleukin-10 mRNA expression in peripheral leukocytes predicts poor outcome and diminished human leukocyte antigen-DR expression on monocytes in septic patients. J Surg Res 2008, 147: 1-8. 10.1016/j.jss.2007.07.009PubMed
70.
Rossato M, Curtale G, Tamassia N, Castellucci M, Mori L, Gasperini S, Mariotti B, De Luca M, Mirolo M, Cassatella MA, Locati M, Bazzoni F: IL-10-induced microRNA-187 negatively regulates TNF-alpha, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proc Natl Acad Sci U S A 2012, 109: E3101-3110. 10.1073/pnas.1209100109PubMedCentralPubMed
71.
Nathan C: Points of control in inflammation. Nature 2002, 420: 846-852. 10.1038/nature01320PubMed
72.
Ratjen F, Doring G: Cystic fibrosis. Lancet 2003, 361: 681-689. 10.1016/S0140-6736(03)12567-6PubMed
73.
Jain K, Smyth AR: Current dilemmas in antimicrobial therapy in cystic fibrosis. Expert Rev Respir Med 2012, 6: 407-422. 10.1586/ers.12.39PubMed
74.
Pier GB: The challenges and promises of new therapies for cystic fibrosis. J Exp Med 2012, 209: 1235-1239. 10.1084/jem.20121248PubMedCentralPubMed
75.
Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Döring G: Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012, 11: 363-382. 10.1016/j.jcf.2012.07.003PubMed
76.
del Campo R, Martínez E, del Fresno C, Alenda R, Gómez-Piña V, Fernández-Ruíz I, Siliceo M, Jurado T, Toledano V, Arnalich F, García-Río F, López-Collazo E: Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients. PLoS One 2011, 6: e29577. 10.1371/journal.pone.0029577PubMedCentralPubMed
77.
Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340: 115-126. 10.1056/NEJM199901143400207PubMed
78.
Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352: 1685-1695. 10.1056/NEJMra043430PubMed
79.
Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I: Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003, 108: 2905-2910. 10.1161/01.CIR.0000101921.93016.1CPubMed
80.
Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997, 96: 396-399. 10.1161/01.CIR.96.2.396PubMed
81.
Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT: PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 2012, 249: 158-175. 10.1111/j.1600-065X.2012.01146.xPubMedCentralPubMed
82.
Arnalich F, Codoceo R, Lopez-Collazo E, Montiel C: Circulating cell-free mitochondrial DNA: a better early prognostic marker in patients with out-of-hospital cardiac arrest. Resuscitation 2012, 83: e162-e163. 10.1016/j.resuscitation.2012.03.032PubMed
83.
Schon EA, DiMauro S, Hirano M: Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet 2012, 13: 878-890.PubMedCentralPubMed
84.
Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22: 231-237. 10.1016/j.coi.2010.01.009PubMed
85.
Mantovani A, Sica A, Allavena P, Garlanda C, Locati M: Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009, 70: 325-330. 10.1016/j.humimm.2009.02.008PubMed
86.
Soares-Schanoski A, Jurado T, Córdoba R, Siliceo M, Fresno CD, Gómez-Piña V, Toledano V, Vallejo-Cremades MT, Alfonso-Iñiguez S, Carballo-Palos A, Fernández-Ruiz I, Cubillas-Zapata C, Biswas SK, Arnalich F, García-Río F, López-Collazo E: Impaired antigen presentation and potent phagocytic activity identifying tumor-tolerant human monocytes. Biochem Biophys Res Commun 2012, 423: 331-337. 10.1016/j.bbrc.2012.05.124PubMed
87.
88.
Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, Uehara H, Yano S, Ledford JG, Sone S, Nishioka Y: Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am J Pathol 2013, 182: 1843-1853. 10.1016/j.ajpath.2013.01.030PubMedCentralPubMed
89.
Herrera M, Herrera A, Domínguez G, Silva J, García V, García JM, Gómez I, Soldevilla B, Muñoz C, Provencio M, Campos-Martin Y, García De Herreros A, Casal I, Bonilla F, Peña C: Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci 2013, 104: 437-444. 10.1111/cas.12096PubMed
90.
Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J: Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 2013, 12: 259-267.PubMed
91.
Tang X, Mo C, Wang Y, Wei D, Xiao H: Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013, 138: 93-104. 10.1111/imm.12023PubMedCentralPubMed
92.
Sica A, Rubino L, Mancino A, Larghi P, Porta C, Rimoldi M, Solinas G, Locati M, Allavena P, Mantovani A: Targeting tumour-associated macrophages. Expert Opin Ther Targets 2007, 11: 1219-1229. 10.1517/14728222.11.9.1219PubMed
93.
Miklossy J: Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med 2011, 13: e30.PubMed
94.
Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Becher H, Hacke W: Recent infection as a risk factor for cerebrovascular ischemia. Stroke 1995, 26: 373-379. 10.1161/01.STR.26.3.373PubMed
95.
Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Hamilton F, Kreitsch P, Mackert BM, Nabavi DG, Nolte CH, Pöhls W, Schmehl I, Schmitz B, von Brevern M, Walter G, Heuschmann PU, Berlin Stroke Register Investigators: Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011, 77: 965-972. 10.1212/WNL.0b013e31822dc795PubMed
96.
Meisel C, Meisel A: Suppressing immunosuppression after stroke. N Engl J Med 2011, 365: 2134-2136. 10.1056/NEJMcibr1112454PubMed
97.
Schulze J, Zierath D, Tanzi P, Cain K, Shibata D, Dressel A, Becker K: Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 2013, 44: 246-248. 10.1161/STROKEAHA.112.676072PubMedCentralPubMed
98.
Aneja RK, Tsung A, Sjodin H, Gefter JV, Delude RL, Billiar TR, Fink MP: Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol 2008, 84: 1326-1334. 10.1189/jlb.0108030PubMedCentralPubMed
99.
Zhang J, Takahashi HK, Liu K, Wake H, Liu R, Maruo T, Date I, Yoshino T, Ohtsuka A, Mori S, Nishibori M: Anti-high mobility group box-1 monoclonal antibody protects the blood–brain barrier from ischemia-induced disruption in rats. Stroke 2011, 42: 1420-1428. 10.1161/STROKEAHA.110.598334PubMed
100.
Tong H, Tang Y, Chen Y, Yuan F, Liu Z, Peng N, Tang L, Su L: HMGB1 activity inhibition alleviating liver injury in heatstroke. J Trauma Acute Care Surg 2013, 74: 801-807. 10.1097/TA.0b013e31827e9a65PubMed
101.
Bryant HU, Bernton EW, Holaday JW: Morphine pellet-induced immunomodulation in mice: temporal relationships. J Pharmacol Exp Ther 1988, 245: 913-920.PubMed
102.
Ocasio FM, Jiang Y, House SD, Chang SL: Chronic morphine accelerates the progression of lipopolysaccharide-induced sepsis to septic shock. J Neuroimmunol 2004, 149: 90-100. 10.1016/j.jneuroim.2003.12.016PubMed
103.
Breslow JM, Monroy MA, Daly JM, Meissler JJ, Gaughan J, Adler MW, Eisenstein TK: Morphine, but not trauma, sensitizes to systemic Acinetobacter baumannii infection. J Neuroimmune Pharmacol 2011, 6: 551-565. 10.1007/s11481-011-9303-6PubMedCentralPubMed
104.
Banerjee S, Meng J, Das S, Krishnan A, Haworth J, Charboneau R, Zeng Y, Ramakrishnan S, Roy S: Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. Sci Rep 1977, 2013: 3.
Metadata
Title
Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences
Authors
Eduardo López-Collazo
Carlos del Fresno
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2013
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13110

Other articles of this Issue 6/2013

Critical Care 6/2013 Go to the issue

Research

End-stage renal disease and outcome in a surgical intensive care unit

Research

An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock

Commentary

Hyperglycemia in the intensive care unit: is insulin the only option?

Research

Effects of thoracic epidural anesthesia on survival and microcirculation in severe acute pancreatitis: a randomized experimental trial

Commentary

Gut instinct

Research

Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock – a systematic review and meta-analysis